tissue plasminogen activator

tissue plasminogen activator

美 　英

• 网络组织型纤溶酶原激活剂；组织型纤溶酶原激活物；组织纤维蛋白溶酶原激活剂

英汉解释

n.	1. an anticlotting enzyme that is produced naturally in blood vessel linings and is genetically engineered for use in treating heart attacks, dissolving blood clots, and preventing heart muscle damage

例句

Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.

急性缺血性卒中患应用重组组织纤溶酶原激活剂治疗的效用成本：一项系统性回顾

A drug called tissue plasminogen activator -- tPA -- dissolves clots and restores blood flow.

而一种称为组织纤维蛋白溶酶原激活物（tPA）的药物可以溶解血块，并恢复血液流通。

Because of extensive purpura fulminans with skin necrosis recombinant tissue plasminogen activator (rt-PA) was used.

由于广泛的暴发性紫癜皮肤坏死与重组组织型纤溶酶原激活剂（酶原激活剂）的使用。

NIHSS scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.

在两个试验中，在组织纤维蛋白溶酶原激活剂使用前，都先用NIHSS评分。

Intravenous thrombolysis therapies in acute myocardial infarction with the reconstructive tissue plasminogen activator in prehospital care

急性心肌梗死院前应用重组组织型纤溶酶原激活剂溶栓研究

Clinical Thrombolytic Trial of A New Type of Tissue-Plasminogen Activator in Patients with Acute Myocardial Infarction

一种新的人组织纤溶酶原激活剂对急性心肌梗死的溶栓效果

Discussion for the Problems in Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Cerebral Infarction

急性脑梗死静脉溶栓治疗的难点与对策

Comparison of thrombolytic therapy with recombinant tissue plasminogen activator and urokinase for acute myocardial infarction

尿激酶与重组织型纤溶酶原激活剂静脉溶栓治疗急性心肌梗死

The efficacy of thrombolysis with recombinant tissue plasminogen activator as compared with urokinase for acute myocardial infarction

重组组织型纤溶酶原激活剂和尿激酶治疗急性心肌梗死的疗效比较

Combined intravenous and intra-arterial infusion of recombinant tissue plasminogen activator for treatment of acute ischemic stroke

重组组织型纤溶酶原激活剂动静脉联合溶栓治疗急性缺血性卒中

Recombinant tissue plasminogen activator for treatment of fibrinous membranes after cataract surgery

重组组织型纤维蛋白酶原激活剂治疗白内障手术后的纤维蛋白膜

The mechanism of the regulation of calcium to the expression of tissue plasminogen activator in epidermis

表皮细胞中钙离子调节组织型纤溶酶原激活剂表达的机制

Thrombolysis With Tissue Plasminogen Activator Alters Adhesion Molecule Expression in the Ischemic Rat Brain

组织纤溶酶原激活物溶栓治疗缺血性卒中大鼠导致大脑中粘附分子表达改变-评论

Construction of tissue plasminogen activator eukaryotic expression vector and its expression in MCF-7 cell line

组织型纤溶酶原激活剂真核表达载体的构建及其在乳癌细胞系MCF-7中的瞬时表达

The current status and progress of recombinant tissue plasminogen activator for treatment of ischemic stroke

重组组织型纤溶酶原激活剂治疗缺血性卒中的现状与进展

Recovery of blood-nerve barrier is delayed in tissue plasminogen activator gene knockout mice after sciatic nerve crush

组织型纤溶酶原激活剂促进小鼠坐骨神经血-神经屏障损伤后的修复

Vitrectomy combined with tissue plasminogen activator and fraxiparine for fibrin exudation caused by bacterial endophthalmitis in rabbits

玻璃体切割术联合组织型纤溶酶原激活物和速避凝治疗兔细菌性眼内炎所致纤维蛋白渗出

Regulation of tissue plasminogen activator expression by EGF in epidermal keratinocytes of mouse

EGF对小鼠角质形成细胞中组织型纤溶酶原激活剂表达的调节

The regulatory effect of tissue plasminogen activator involved in central nervous insult

组织型纤溶酶原激活物在中枢神经损伤中的调节作用

Nursing care of patients with acute myocardial infarction treated with recombinant human tissue plasminogen activator

重组人组织纤溶酶原激活剂治疗急性心肌梗死病人的护理

Expression of tissue plasminogen activator and inhibitor-1 after acute pulmonary thromboembolism in rabbit

肺血栓栓塞后组织型纤溶酶原激活物及其抑制物-1在肺动脉中的表达

The effect of recombinant human tissue plasminogen activator on coagulation function and immune response in pigs

重组人类组织型纤溶酶原激活剂对家猪凝血和免疫指标的影响

R-TPA recombinant tissue plasminogen activator

重组的组织型纤溶酶原激活物

Construction of human tissue plasminogen activator minigene

人组织型纤溶酶原激活剂突变体微小基因的构建

The Study of Relationship between Tissue Plasminogen Activator and Diseases Related to Thrombus

组织型纤溶酶原激活物与血栓相关性疾病的关系研究

The Study on Tissue Plasminogen Activator Change in Stroke Patients

缺血性脑卒中患者血纤溶活性变化规律的研究

Association of Hyperdense Middle Cerebral Artery Sign With Clinical Outcome in Patients Treated With Tissue Plasminogen Activator

中风患者高密度大脑中动脉征象与组织纤溶酶原激活剂治疗临床预后的关系